SEOUL, South Korea, Aug. 25, 2015 /PRNewswire/ -- CPhI Korea -- the most comprehensive pure pharma event focused event in Korea -- will return to COEX in Seoul, South Korea, from 7th to 9th September 2015.
CPhI Korea 2015 (www.cphikorea.com) is co-organised by UBM and the Korea Pharmaceutical Traders Association (KPTA) and sponsored by the Ministry of Food and Drug Safety (MFDS), the Korea Drug Research Association (KDRA), and the Korea Biomedicine Industry Association (KOBIA).
CPhI Korea 2015 will be consisted of an exhibition with around 150 pharmaceutical companies from 11 countries, a conference programme with topics covering Korea's pharmaceutical market registration system for overseas companies and overseas market trends and registration system for Korean companies' overseas market expansion, and a 1:1 business matchmaking programme for visitors and exhibitors to provide new leads and business partners utilising the extensive CPhI global network.
Including Korea's representative pharmaceutical companies -- Hanmi Pharm, Daewoong, Dongkook Pharm, Ajinomtogenexine, Aminologics, Anton Paar Korea, Biostream Technologies, Changsung Softgel, CMG Pharmaceutical, CTC Bio, Daebong LS, Daehwa Pharmaceutical, Daihan FCS, Dasan Medichem, Dongwoo Syntech, Duksung, Estech Pharma, GFTEC, HUSTECH, Junghyun Plant, Kolmar Korea, KORASIAN Healthcare, Korea Pharma, Korea United Pharm, QBD, Samoh Pharm, SEDNAENG, SKY Softgel, Sungji Corporation, SungYi Pharm, Taiguk Pharm, Wooridul Pharmaceutical, and Wooshin Medics will accelerate overseas market expansion and sales promotion at CPhI Korea 2015. Also Merck Ltd. Korea, the world's second largest pharmaceutical company, has confirmed its participation for global commercialization.
Thanks to the strong UBM overseas network, China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and China Council for the Promotion of International Trade (CCPIT) will be presenting China Pavilions with the leading Chinese pharmaceutical companies, and the Russian ministry will present a Russia Pavilion for the first time with around 10 Russian pharmaceutical companies. In addition, KBI Biopharma from USA, Tata Chemicals and Intertek from UK, BCN Peptides from Spain, Metalco-Alupack from Italy, Quinta Analytics from Czech Republic, SibPribor from Russia, Word medicine from Turkey, and PANTHEON FZE from United Arab Emirates will add the diversity to the event. Moreover, Chinese companies including Qi-chem, Sinolite, Zhejiang Tianyu Pharmaceutical and Indian companies such as Pharmalab, Alchem, and Zim Laboratories and many more will join the show. CPhI Korea is generating a high level of interest in the industry and the industry experts from 83 countries have already pre-registered to attend the event.
CPhI Korea 2015 Conference features a wide range of top-level speakers from the government, academia and the industry. On September 7th, Mr. Zhang Zhongpeng, Deputy Director of CCMHPIE, will speak about the strategy for entering Chinese market and Chinese Pharmaceutical Registration. On September 8th, Mr. Robert Fish, Senior Consultant of EAS Consulting Group, will present on how to prepare for a FDA inspection and FDA data integrity. Ms. Miho Tabata, Chief reviewer of the Pharmaceuticals and Medical Devices Agency (PMDA) will talk about how to register to generic medicines in Japan and Mr. Kentaro Hashimoto, technical officer of PMDA, will explain how to register to DMF in Japan. On September 9th, Ms. Hojeong Kim, deputy director of drug review management division in the National Institute of Food and Drug Safety Evaluation (NIFDS), will speak about drug regulatory system in Korea, and Ms. Kyungshin Lee, deputy director of pharmaceutical standardization division in NIFDS will share on how to register to DMF in Korea.
CPhI Korea 2015 also hosts an exhibitor showcase for the exhibitors to introduce their new products & services, or the result of research and business developments, etc. On September 7th, Thomas Jung, vice president in business development department of KBI Biopharma, will present on "Analytical Support for Protein Therapeutics." On September 8th, Intertek will present on "Strategic Analysis Studies to Support Regulatory Approval for Biological Therapeutics."
Through the participation of leading pharmaceutical companies from numerous countries, CPhI Korea 2015 will provide an unrivaled platform for domestic and international pharmaceutical companies to augment the next stage of development in the rapidly maturing Korean market.
For media enquiries, please contact:
Evelyn Kang
UBM Korea Corporation
T: +82-2-6715-5400
E: evelyn.kang@ubm.com
